Impact of PK/PD, Disease Models and Personalized Medicine to Influence FDA Decisions
dc.contributor.author | Powell, Robert | |
dc.date.accessioned | 2006-11-19T21:25:35Z | |
dc.date.available | 2006-11-19T21:25:35Z | |
dc.date.issued | 2006-10-26 | |
dc.identifier.uri | http://hdl.handle.net/1808/1173 | |
dc.format.extent | 2607082 bytes | |
dc.format.mimetype | application/pdf | |
dc.language | en | |
dc.relation.ispartofseries | SC | |
dc.relation.ispartofseries | 07 | |
dc.title | Impact of PK/PD, Disease Models and Personalized Medicine to Influence FDA Decisions | |
dc.type | Presentation | |
kusw.oastatus | na | |
kusw.oapolicy | This item does not meet KU Open Access policy criteria. | |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
-
Short course 7: From Bench-Top to Clinic: How Pre-Clinical Studies can Guide Clinical Testing of Promising Drug Molecules [1]
Faculty organizer: Sandy Allerheiligen Ph.D.; Eli Lilly and Company